Financial PerformanceEXAS delivered strong profitability, with adj EBITDA coming in significantly above expectations at $100M.
Pipeline MilestonesSeveral pipeline milestones expected before year-end could be catalysts for the stock, such as Cologuard-Plus FDA approval and initial blood-based CRC screening data from Blue-C cohort.
Sales Force ExpansionManagement indicated they completed sales force expansion in May and expects full productivity in 6 months — driving the contribution growth.